BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kobayashi T, Iwama S, Yasuda Y, Okada N, Tsunekawa T, Onoue T, Takagi H, Hagiwara D, Ito Y, Morishita Y, Goto M, Suga H, Banno R, Yokota K, Hase T, Morise M, Hashimoto N, Ando M, Kiyoi H, Gotoh M, Ando Y, Akiyama M, Hasegawa Y, Arima H. Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study. J Endocr Soc 2018;2:241-51. [PMID: 29600292 DOI: 10.1210/js.2017-00432] [Cited by in Crossref: 102] [Cited by in F6Publishing: 107] [Article Influence: 20.4] [Reference Citation Analysis]
Number Citing Articles
1 Shalit A, Sarantis P, Koustas E, Trifylli EM, Matthaios D, Karamouzis MV. Predictive Biomarkers for Immune-Related Endocrinopathies following Immune Checkpoint Inhibitors Treatment. Cancers (Basel) 2023;15. [PMID: 36672324 DOI: 10.3390/cancers15020375] [Reference Citation Analysis]
2 Dwivedi SN, Kalaria T, Buch H. Thyroid autoantibodies. J Clin Pathol 2023;76:19-28. [PMID: 36270794 DOI: 10.1136/jcp-2022-208290] [Reference Citation Analysis]
3 Pani F, Yasuda Y, Rousseau ST, Bermea KC, Roshanmehr S, Wang R, Yegnasubramanian S, Caturegli P, Adamo L. Preconditioning of the immune system modulates the response of papillary thyroid cancer to immune checkpoint inhibitors. J Immunother Cancer 2022;10. [PMID: 36521928 DOI: 10.1136/jitc-2022-005538] [Reference Citation Analysis]
4 de Filette JMK, André S, De Mey L, Aspeslagh S, Karmali R, Van der Auwera BJ, Bravenboer B. Durvalumab-induced thyroiditis in a patient with non-small cell lung carcinoma: a case report and review of pathogenic mechanisms. BMC Endocr Disord 2022;22:291. [PMID: 36419114 DOI: 10.1186/s12902-022-01190-5] [Reference Citation Analysis]
5 Wu L, Xu Y, Wang X, Cheng X, Zhang Y, Wang Y, Fan X, Zhao H, Liu H, Chai X, Zhang L, Wang M, Li N, Pan H, Lian X. Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study.. [DOI: 10.21203/rs.3.rs-2210602/v1] [Reference Citation Analysis]
6 Tison A, Garaud S, Chiche L, Cornec D, Kostine M. Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases. Nat Rev Rheumatol 2022. [PMID: 36198831 DOI: 10.1038/s41584-022-00841-0] [Reference Citation Analysis]
7 Chera A, Stancu AL, Bucur O. Thyroid-related adverse events induced by immune checkpoint inhibitors. Front Endocrinol 2022;13:1010279. [DOI: 10.3389/fendo.2022.1010279] [Reference Citation Analysis]
8 Gannichida A, Nakazawa Y, Kageyama A, Utsumi H, Kuwano K, Kawakubo T. Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer. World J Clin Oncol 2022; 13(7): 641-651 [DOI: 10.5306/wjco.v13.i7.641] [Reference Citation Analysis]
9 Chye A, Allen I, Barnet M, Burnett DL. Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy. Front Oncol 2022;12:894015. [DOI: 10.3389/fonc.2022.894015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Deligiorgi MV, Trafalis DT. The continuum of care of anticancer treatment-induced hypothyroidism in patients with solid non thyroid tumors: time for an intimate collaboration between oncologists and endocrinologists. Expert Rev Clin Pharmacol 2022. [PMID: 35757870 DOI: 10.1080/17512433.2022.2093714] [Reference Citation Analysis]
11 Les I, Pérez-Francisco I, Cabero M, Sánchez C, Hidalgo M, Teijeira L, Arrazubi V, Domínguez S, Anaut P, Eguiluz S, Elejalde I, Herrera A, Martínez M. Prediction of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors With a Panel of Autoantibodies: Protocol of a Multicenter, Prospective, Observational Cohort Study. Front Pharmacol 2022;13:894550. [PMID: 35721217 DOI: 10.3389/fphar.2022.894550] [Reference Citation Analysis]
12 Rahman MM, Behl T, Islam MR, Alam MN, Islam MM, Albarrati A, Albratty M, Meraya AM, Bungau SG. Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer. Molecules 2022;27:3798. [PMID: 35744922 DOI: 10.3390/molecules27123798] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
13 Chieng JHL, Htet ZW, Zhao JJ, Tai ES, Tay SH, Huang Y, Wong A, Yang SP. Clinical Presentation of Immune-Related Endocrine Adverse Events during Immune Checkpoint Inhibitor Treatment. Cancers 2022;14:2687. [DOI: 10.3390/cancers14112687] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Kotwal A, Mcleod DS. Thyroid Dysfunction from Treatments for Solid Organ Cancers. Endocrinology and Metabolism Clinics of North America 2022. [DOI: 10.1016/j.ecl.2021.12.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Sovich S, Lechner MG. Immune Checkpoint Inhibitor–Associated Thyroiditis Risk Lurking in the Ultrasound. Clinical Thyroidology 2022;34:226-8. [DOI: 10.1089/ct.2022;34.226-228] [Reference Citation Analysis]
16 Yuen KCJ, Samson SL, Bancos I, Gosmanov AR, Jasim S, Fecher LA, Weber JS. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGY (AACE) DISEASE STATE CLINICAL REVIEW EVALUATION AND MANAGEMENT OF IMMUNE CHECKPOINT INHIBITOR-MEDIATED ENDOCRINOPATHIES: A PRACTICAL CASE-BASED CLINICAL APPROACH. Endocr Pract 2022:S1530-891X(22)00489-X. [PMID: 35477029 DOI: 10.1016/j.eprac.2022.04.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Poto R, Troiani T, Criscuolo G, Marone G, Ciardiello F, Tocchetti CG, Varricchi G. Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events. Front Immunol 2022;13:804597. [PMID: 35432346 DOI: 10.3389/fimmu.2022.804597] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
18 Olsen TA, Zhuang TZ, Caulfield S, Martini DJ, Brown JT, Carthon BC, Kucuk O, Harris W, Bilen MA, Nazha B. Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy. Front Endocrinol 2022;13:779915. [DOI: 10.3389/fendo.2022.779915] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
19 Barth DA, Stanzer S, Spiegelberg J, Bauernhofer T, Absenger G, Posch F, Lipp R, Halm M, Szkandera J, Balic M, Gerger A, Smolle MA, Hutterer GC, Klec C, Jost PJ, Kargl J, Stradner M, Pichler M. Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan-cancer study. Cancer Med 2022. [PMID: 35297215 DOI: 10.1002/cam4.4675] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
20 Izawa N, Shiokawa H, Onuki R, Hamaji K, Morikawa K, Saji H, Ohashi H, Kasugai S, Hayakawa N, Ohara T, Sunakawa Y. The clinical utility of comprehensive measurement of autoimmune disease-related antibodies in patients with advanced solid tumors receiving immune checkpoint inhibitors: a retrospective study. ESMO Open 2022;7:100415. [PMID: 35247869 DOI: 10.1016/j.esmoop.2022.100415] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Sagie S, Gadot M, Levartovsky M, Gantz Sorotsky H, Berger R, Sarfaty M, Percik R. Immune-Related Thyroiditis as a Predictor for Survival in Metastatic Renal Cell Carcinoma. Cancers (Basel) 2022;14:875. [PMID: 35205622 DOI: 10.3390/cancers14040875] [Reference Citation Analysis]
22 George AS, Fernandez CJ, Eapen D, Pappachan JM. Organ-specific Adverse Events of Immune Checkpoint Inhibitor Therapy, with Special Reference to Endocrinopathies. touchREV Endocrinol 2021;17:21-32. [PMID: 35118443 DOI: 10.17925/EE.2021.17.1.21] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
23 Kotwal A. Increased Risk of Thyroid Dysfunction with Combination PD-1 and CTLA-4 Blockade, Even in the Absence of Positive Thyroid Antibodies. Clinical Thyroidology 2022;34:52-5. [DOI: 10.1089/ct.2022;34.52-55] [Reference Citation Analysis]
24 Cómbita Rojas AL. Autoantibodies: A manifestation of immune related adverse events of cancer immunotherapy. Revista Colombiana de Reumatología (English Edition) 2022;29:1-2. [DOI: 10.1016/j.rcreue.2022.01.001] [Reference Citation Analysis]
25 Cómbita Rojas AL. Autoanticuerpos: una manifestación de los eventos adversos inmunológicos de la inmunoterapia en cáncer. Revista Colombiana de Reumatología 2022;29:1-2. [DOI: 10.1016/j.rcreu.2021.11.001] [Reference Citation Analysis]
26 Do TVC, Gudipati MK, Ganti SS, Depa J, Sajnani K. Immunotherapy: A Case Series. Cureus 2021;13:e19726. [PMID: 34934589 DOI: 10.7759/cureus.19726] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Zhang Z, Zhou J, Verma V, Liu X, Wu M, Yu J, Chen D. Crossed Pathways for Radiation-Induced and Immunotherapy-Related Lung Injury. Front Immunol 2021;12:774807. [PMID: 34925345 DOI: 10.3389/fimmu.2021.774807] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
28 Bardoscia L, Pasinetti N, Triggiani L, Cozzi S, Sardaro A. Biological Bases of Immune-Related Adverse Events and Potential Crosslinks With Immunogenic Effects of Radiation. Front Pharmacol 2021;12:746853. [PMID: 34790123 DOI: 10.3389/fphar.2021.746853] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
29 Iwama S, Kobayashi T, Yasuda Y, Okuji T, Ito M, Ando M, Zhou X, Yamagami A, Onoue T, Kawaguchi Y, Miyata T, Sugiyama M, Takagi H, Hagiwara D, Suga H, Banno R, Hase T, Morise M, Wakahara K, Yokota K, Kato M, Nishio N, Tanaka C, Miyata K, Ogura A, Ito T, Sawada T, Shimokata T, Niimi K, Ohka F, Ishigami M, Gotoh M, Hashimoto N, Saito R, Kiyoi H, Kajiyama H, Ando Y, Hibi H, Sone M, Akiyama M, Kodera Y, Arima H. Increased risk of thyroid dysfunction by PD-1 and CTLA-4 blockade in patients without thyroid autoantibodies at baseline. J Clin Endocrinol Metab 2021:dgab829. [PMID: 34791304 DOI: 10.1210/clinem/dgab829] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
30 Percik R, Liel Y, Urban D, Bar J, Ben-Ami E, Abu Tailakh M. Thyroid dysfunction and survival in cancer patients treated with immune checkpoint inhibitors: analyses from a large single tertiary cancer center database. Acta Oncol 2021;60:1466-71. [PMID: 34379562 DOI: 10.1080/0284186X.2021.1958006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Deligiorgi MV, Sagredou S, Vakkas L, Trafalis DT. The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries. Cancers (Basel) 2021;13:5277. [PMID: 34771441 DOI: 10.3390/cancers13215277] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
32 Kobayashi T, Iwama S, Yasuda Y, Okada N, Okuji T, Ito M, Onoue T, Goto M, Sugiyama M, Tsunekawa T, Takagi H, Hagiwara D, Ito Y, Suga H, Banno R, Yokota K, Hase T, Morise M, Hashimoto N, Ando M, Fujimoto Y, Hibi H, Sone M, Ando Y, Akiyama M, Hasegawa Y, Arima H. Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study. J Immunother Cancer 2020;8:e000779. [PMID: 32606047 DOI: 10.1136/jitc-2020-000779] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 17.0] [Reference Citation Analysis]
33 Takahashi Y, Sunakawa Y, Inoue E, Kawabata R, Ishiguro A, Kito Y, Akamaru Y, Takahashi M, Yabusaki H, Matsuyama J, Makiyama A, Tsuda M, Suzuki T, Yasui H, Matoba R, Kawakami H, Nakajima TE, Muro K, Ichikawa W, Fujii M. Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08). Gastric Cancer 2021. [PMID: 34427838 DOI: 10.1007/s10120-021-01237-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
34 Ito T, Ishigami M, Yamamoto T, Mizuno K, Yamamoto K, Imai N, Ishizu Y, Honda T, Kawashima H, Yasuda S, Toyoda H, Yokota K, Hase T, Nishio N, Maeda O, Kato M, Hashimoto N, Hibi H, Kodera Y, Sone M, Ando Y, Akiyama M, Shimoyama Y, Fujishiro M. Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies. Hepatol Int 2021. [PMID: 34373964 DOI: 10.1007/s12072-021-10238-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
35 Yasuda Y, Iwama S, Sugiyama D, Okuji T, Kobayashi T, Ito M, Okada N, Enomoto A, Ito S, Yan Y, Sugiyama M, Onoue T, Tsunekawa T, Ito Y, Takagi H, Hagiwara D, Goto M, Suga H, Banno R, Takahashi M, Nishikawa H, Arima H. CD4+ T cells are essential for the development of destructive thyroiditis induced by anti-PD-1 antibody in thyroglobulin-immunized mice. Sci Transl Med 2021;13:eabb7495. [PMID: 33980577 DOI: 10.1126/scitranslmed.abb7495] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
36 Zhan L, Feng HF, Liu HQ, Guo LT, Chen C, Yao XL, Sun SR. Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management. Front Endocrinol (Lausanne) 2021;12:649863. [PMID: 34177799 DOI: 10.3389/fendo.2021.649863] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
37 Les I, Martínez M, Narro A, Pérez I, Sánchez C, Puntí L, Anaut P, Eguiluz S, Herrera A, Domínguez S. Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies. Ann Med 2021;53:762-9. [PMID: 34060971 DOI: 10.1080/07853890.2021.1931956] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
38 Kobayashi T, Iwama S, Sugiyama D, Yasuda Y, Okuji T, Ito M, Ito S, Sugiyama M, Onoue T, Takagi H, Hagiwara D, Ito Y, Suga H, Banno R, Nishikawa H, Arima H. Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors. J Immunother Cancer 2021;9:e002493. [PMID: 34011534 DOI: 10.1136/jitc-2021-002493] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
39 Iwama S, Kobayashi T, Arima H. Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors. Endocrinol Metab (Seoul) 2021;36:312-21. [PMID: 33934588 DOI: 10.3803/EnM.2021.1007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
40 Wright JJ, Powers AC, Johnson DB. Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol 2021;17:389-99. [PMID: 33875857 DOI: 10.1038/s41574-021-00484-3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 48] [Article Influence: 19.5] [Reference Citation Analysis]
41 Peiffert M, Cugnet-Anceau C, Dalle S, Chikh K, Assaad S, Disse E, Raverot G, Borson-Chazot F, Abeillon-du Payrat J. Graves' Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review). Cancers (Basel) 2021;13:1944. [PMID: 33920721 DOI: 10.3390/cancers13081944] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
42 Yoon JH, Hong AR, Kim HK, Kang HC. Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors. Endocrinol Metab (Seoul) 2021;36:413-23. [PMID: 33820396 DOI: 10.3803/EnM.2020.906] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
43 Shibata Y, Murakami S, Kato T. Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factors. Expert Opin Drug Saf 2021;20:537-47. [PMID: 33650443 DOI: 10.1080/14740338.2021.1898584] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Lui DTW, Lee CH, Tang V, Fong CHY, Lee ACH, Chiu JWY, Leung RCY, Kwok GGW, Li BCW, Cheung TT, Woo YC, Lam KSL, Yau T. Thyroid Immune-Related Adverse Events in Patients with Cancer Treated with anti-PD1/anti-CTLA4 Immune Checkpoint Inhibitor Combination: Clinical Course and Outcomes. Endocr Pract 2021:S1530-891X(21)00030-6. [PMID: 33581327 DOI: 10.1016/j.eprac.2021.01.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
45 Willsmore ZN, Harris RJ, Crescioli S, Hussein K, Kakkassery H, Thapa D, Cheung A, Chauhan J, Bax HJ, Chenoweth A, Laddach R, Osborn G, McCraw A, Hoffmann RM, Nakamura M, Geh JL, MacKenzie-Ross A, Healy C, Tsoka S, Spicer JF, Papa S, Barber L, Lacy KE, Karagiannis SN. B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies. Front Immunol 2020;11:622442. [PMID: 33569063 DOI: 10.3389/fimmu.2020.622442] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
46 George AS, Fernandez CJ, Eapen D, Pappachan JM; Department of Medical Oncology, Lakeshore Hospital, Cochin, Kerala, India, Department of Endocrinology, Pilgrim Hospital, United Lincolnshire Hospitals NHS Trust, Boston, UK, Department of Endocrinology, Pilgrim Hospital, United Lincolnshire Hospitals NHS Trust, Boston, UK, Department of Endocrinology & Metabolism, Lancashire Teaching Hospitals NHS Trust, Preston, UK, Manchester Metropolitan University, Manchester, UK, The University of Manchester, Manchester, UK. Organ-specific Adverse Events of Immune Checkpoint Inhibitor Therapy, with Special Reference to Endocrinopathies. European Endocrinology 2021;1:21. [DOI: 10.17925/ee.2021.1.1.21] [Reference Citation Analysis]
47 Brilli L, Danielli R, Campanile M, Secchi C, Ciuoli C, Calabrò L, Pilli T, Cartocci A, Pacini F, Di Giacomo AM, Castagna MG. Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy. J Endocrinol Invest 2021;44:1719-26. [PMID: 33367977 DOI: 10.1007/s40618-020-01480-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
48 Sheehan K, Price C, Hafez N. Optimizing Care for Patients With Adverse Events From Immunotherapeutics. Cancer J 2020;26:537-42. [PMID: 33298725 DOI: 10.1097/PPO.0000000000000492] [Reference Citation Analysis]
49 Nasser NJ, Gorenberg M, Agbarya A. First line Immunotherapy for Non-Small Cell Lung Cancer. Pharmaceuticals (Basel) 2020;13:E373. [PMID: 33171686 DOI: 10.3390/ph13110373] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
50 Wang M, Liang H, Wang W, Zhao S, Cai X, Zhao Y, Li C, Cheng B, Xiong S, Li J, He J, Liang W. Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials. Cancer 2021;127:777-86. [PMID: 33119182 DOI: 10.1002/cncr.33270] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
51 Paydary K, Zain Farooq M, Mangla A. History of Radiation to the Neck Increases the Risk of Denovo Thyroid Dysfunction after Receiving Immune Checkpoint Inhibitors. Endocrines 2020;1:82-89. [DOI: 10.3390/endocrines1020008] [Reference Citation Analysis]
52 Yamauchi I, Taura D, Hakata T, Fujita H, Okamoto K, Ueda Y, Fujii T, Inagaki N. Clinical features and thyroid dysfunction in adverse events involving the pituitary gland during PD-1 blockade therapy. Clin Endocrinol (Oxf) 2021;94:258-68. [PMID: 33037658 DOI: 10.1111/cen.14349] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
53 Xu Y, Fu Y, Zhu B, Wang J, Zhang B. Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities. Front Immunol 2020;11:2023. [PMID: 33123120 DOI: 10.3389/fimmu.2020.02023] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
54 Stelmachowska-Banaś M, Czajka-Oraniec I. Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review. Endocr Connect 2020;9:R207-28. [PMID: 33064663 DOI: 10.1530/EC-20-0342] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
55 Nakazawa Y, Gannichida A, Kageyama A, Utsumi H, Kuwano K, Kawakubo T. Involvement of Neutrophil-lymphocyte Ratio in Nivolumab Therapy-induced Hypothyroidism. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 2020;46:481-8. [DOI: 10.5649/jjphcs.46.481] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
56 Sakamoto K, Fukihara J, Morise M, Hashimoto N. Clinical burden of immune checkpoint inhibitor-induced pneumonitis. Respiratory Investigation 2020;58:305-19. [DOI: 10.1016/j.resinv.2020.05.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
57 Theiler-schwetz V, Trummer C, Richtig E, Richtig G, Pilz S. Schilddrüsenfunktionsstörungen unter Immuncheckpoint-Inhibitor-Therapie. J Klin Endokrinol Stoffw 2020;13:115-118. [DOI: 10.1007/s41969-020-00111-y] [Reference Citation Analysis]
58 Takayama T, Murakami K, Minemura C, Yoshidome R, Yamamura K, Yokoe H. A case of simultaneous double cancer of oral malignant melanoma and lung adenocarcinoma with nivolumab-induced destructive thyroiditis. Jpn J Oral Maxillofac Surg 2020;66:376-381. [DOI: 10.5794/jjoms.66.376] [Reference Citation Analysis]
59 Albrethsen M, Creeden J, Morand S, DeBiase J, Berry B, Stanbery L, Edelman G, Nemunaitis J. Relationship of hypothyroidism and immune response to pegylated IL-10/nivolumab. Immunotherapy 2020;12:1041-6. [PMID: 32808556 DOI: 10.2217/imt-2020-0016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
60 Dudzińska M, Szczyrek M, Wojas-Krawczyk K, Świrska J, Chmielewska I, Zwolak A. Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients-Literature Review. Cancers (Basel) 2020;12:E2314. [PMID: 32824462 DOI: 10.3390/cancers12082314] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
61 Richter MD, Hughes GC, Chung SH, Ezeanuna M, Singh N, Thompson JA. Immunologic adverse events from immune checkpoint therapy. Best Practice & Research Clinical Rheumatology 2020;34:101511. [DOI: 10.1016/j.berh.2020.101511] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
62 Pollack R, Ashash A, Cahn A, Rottenberg Y, Stern H, Dresner-pollak R. Immune Checkpoint Inhibitor-induced Thyroid Dysfunction Is Associated with Higher Body Mass Index. The Journal of Clinical Endocrinology & Metabolism 2020;105:e3620-7. [DOI: 10.1210/clinem/dgaa458] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
63 Nakamura M, Otsuka T, Hayashi R, Horita T, Ota M, Sakurai N, Takano H, Hayashi T, Kumagai M, Yamada S, Arisawa T. Durvalumab-induced Immune-related Hepatitis in a Patient with Non-small Cell Lung Cancer. Intern Med 2020;59:2711-7. [PMID: 32669493 DOI: 10.2169/internalmedicine.4699-20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
64 Rahman W, Conley A, Silver KD. Atezolizumab-induced type 1 diabetes mellitus in a patient with metastatic renal cell carcinoma. BMJ Case Rep 2020;13:e233842. [PMID: 32616532 DOI: 10.1136/bcr-2019-233842] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
65 Okura N, Asano M, Uchino J, Morimoto Y, Iwasaku M, Kaneko Y, Yamada T, Fukui M, Takayama K. Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review. J Clin Med 2020;9:E2033. [PMID: 32610470 DOI: 10.3390/jcm9072033] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
66 Kotwal A, Gustafson MP, Bornschlegl S, Kottschade L, Delivanis DA, Dietz AB, Gandhi M, Ryder M. Immune Checkpoint Inhibitor-Induced Thyroiditis Is Associated with Increased Intrathyroidal T Lymphocyte Subpopulations. Thyroid 2020;30:1440-50. [PMID: 32323619 DOI: 10.1089/thy.2020.0075] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
67 Shibata Y, Murakami S. Safety evaluation of durvalumab for the treatment of non-small-cell lung cancer. Expert Opin Drug Saf 2020;19:653-9. [PMID: 32357806 DOI: 10.1080/14740338.2020.1764936] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
68 Muir CA, Menzies AM, Clifton-Bligh R, Tsang VHM. Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer. Thyroid 2020;30:1458-69. [PMID: 32264785 DOI: 10.1089/thy.2020.0032] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 5.7] [Reference Citation Analysis]
69 Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashta MA, Lambotte O, Mariette X, Prat A, Suárez-Almazor ME. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 2020;6:38. [PMID: 32382051 DOI: 10.1038/s41572-020-0160-6] [Cited by in Crossref: 317] [Cited by in F6Publishing: 343] [Article Influence: 105.7] [Reference Citation Analysis]
70 Lorch JH. Development of Overt Thyroid Dysfunction and Antithyroid Antibodies with Anti-PD-1 Use in Various Cancers Is Associated with Favorable Survival. Clinical Thyroidology 2020;32:221-4. [DOI: 10.1089/ct.2020;32.221-224] [Reference Citation Analysis]
71 Deligiorgi MV, Panayiotidis MI, Trafalis DT. Endocrine adverse events related with immune checkpoint inhibitors: an update for clinicians. Immunotherapy 2020;12:481-510. [PMID: 32345074 DOI: 10.2217/imt-2019-0132] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
72 Basak EA, van der Meer JWM, Hurkmans DP, Schreurs MWJ, Oomen-de Hoop E, van der Veldt AAM, Bins S, Joosse A, Koolen SLW, Debets R, Peeters RP, Aerts JGJV, Mathijssen RHJ, Medici M. Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients. Thyroid 2020;30:966-73. [PMID: 32151195 DOI: 10.1089/thy.2019.0726] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 10.3] [Reference Citation Analysis]
73 Chan KK, Bass AR. Autoimmune complications of immunotherapy: pathophysiology and management. BMJ. [DOI: 10.1136/bmj.m736] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 16.0] [Reference Citation Analysis]
74 Cugnet Anceau C, Abeillon J, Maillet D, Borson-chazot F, Disse E. Les dysthyroïdies sous immunothérapie anti-cancéreuse. Bulletin du Cancer 2020;107:262-71. [DOI: 10.1016/j.bulcan.2019.10.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
75 Kotwal A, Kottschade L, Ryder M. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients. Thyroid 2020;30:177-84. [PMID: 31813343 DOI: 10.1089/thy.2019.0250] [Cited by in Crossref: 68] [Cited by in F6Publishing: 74] [Article Influence: 22.7] [Reference Citation Analysis]
76 Sbardella E, Tenuta M, Sirgiovanni G, Gianfrilli D, Pozza C, Venneri MA, Cortesi E, Marchetti P, Lenzi A, Gelibter AJ, Isidori AM. Thyroid disorders in programmed death 1 inhibitor‐treated patients: Is previous therapy with tyrosine kinase inhibitors a predisposing factor? Clin Endocrinol 2020;92:258-65. [DOI: 10.1111/cen.14135] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
77 Nogueira E, Newsom-Davis T, Morganstein DL. Immunotherapy-induced endocrinopathies: assessment, management and monitoring. Ther Adv Endocrinol Metab. 2019;10:2042018819896182. [PMID: 31903179 DOI: 10.1177/2042018819896182] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
78 Tai D, Choo SP, Chew V. Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. Cancers (Basel) 2019;11:E1926. [PMID: 31816940 DOI: 10.3390/cancers11121926] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
79 Sakakida T, Ishikawa T, Chihara Y, Harita S, Uchino J, Tabuchi Y, Komori S, Asai J, Narukawa T, Arai A, Tsunezuka H, Kosuga T, Konishi H, Moriguchi M, Yasuda H, Hongo F, Inoue M, Hirano S, Ukimura O, Itoh Y, Taguchi T, Takayama K. Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies. Clin Transl Oncol 2020;22:919-27. [PMID: 31576495 DOI: 10.1007/s12094-019-02214-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
80 Arima H, Kobayashi T, Iwama S. 4) Immune-related Adverse Events in Endocrine Organs Induced by Immune Checkpoint Inhibitors. J Jpn Soc Intern Med 2019;108:1788-1792. [DOI: 10.2169/naika.108.1788] [Reference Citation Analysis]
81 Pollack RM, Kagan M, Lotem M, Dresner-pollak R. Baseline TSH Level is Associated with Risk of Anti–PD-1–Induced Thyroid Dysfunction. Endocrine Practice 2019;25:824-9. [DOI: 10.4158/ep-2018-0472] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
82 Horinouchi H, Nishio M, Hida T, Nakagawa K, Sakai H, Nogami N, Atagi S, Takahashi T, Saka H, Takenoyama M, Katakami N, Tanaka H, Takeda K, Satouchi M, Isobe H, Maemondo M, Goto K, Hirashima T, Minato K, Sumiyoshi N, Tamura T. Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies. Cancer Med 2019;8:5183-93. [PMID: 31353840 DOI: 10.1002/cam4.2411] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
83 Yang J, He X, Lv Q, Jing J, Shi H. Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations. Front Pharmacol 2019;10:726. [PMID: 31312140 DOI: 10.3389/fphar.2019.00726] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
84 Connolly C, Bambhania K, Naidoo J. Immune-Related Adverse Events: A Case-Based Approach. Front Oncol 2019;9:530. [PMID: 31293970 DOI: 10.3389/fonc.2019.00530] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
85 Shibaki R, Murakami S, Oki K, Ohe Y. Nivolumab-induced autoimmune encephalitis in an anti-neuronal autoantibody-positive patient. Japanese Journal of Clinical Oncology 2019;49:793-4. [DOI: 10.1093/jjco/hyz087] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
86 Sakakida T, Ishikawa T, Uchino J, Chihara Y, Komori S, Asai J, Narukawa T, Arai A, Kobayashi T, Tsunezuka H, Kosuga T, Konishi H, Hongo F, Inoue M, Hirano S, Ukimura O, Itoh Y, Taguchi T, Takayama K. Clinical features of immune-related thyroid dysfunction and its association with outcomes in patients with advanced malignancies treated by PD-1 blockade. Oncol Lett 2019;18:2140-7. [PMID: 31423288 DOI: 10.3892/ol.2019.10466] [Cited by in Crossref: 13] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
87 Álvarez-Sierra D, Marín-Sánchez A, Ruiz-Blázquez P, de Jesús Gil C, Iglesias-Felip C, González Ó, Casteras A, Costa RF, Nuciforo P, Colobran R, Pujol-Borrell R. Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity. J Autoimmun 2019;103:102285. [PMID: 31182340 DOI: 10.1016/j.jaut.2019.05.013] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 9.8] [Reference Citation Analysis]
88 Jannin A, Penel N, Ladsous M, Vantyghem MC, Do Cao C. Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders. Crit Rev Oncol Hematol. 2019;141:23-35. [PMID: 31202955 DOI: 10.1016/j.critrevonc.2019.05.015] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 7.3] [Reference Citation Analysis]
89 Mazarico I, Capel I, Giménez-Palop O, Albert L, Berges I, Luchtenberg F, García Y, Fernández-Morales LA, De Pedro VJ, Caixàs A, Rigla M. Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors. J Endocrinol Invest 2019;42:1443-50. [PMID: 31093955 DOI: 10.1007/s40618-019-01058-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 6.5] [Reference Citation Analysis]
90 Yamauchi I, Yasoda A, Matsumoto S, Sakamori Y, Kim YH, Nomura M, Otsuka A, Yamasaki T, Saito R, Kitamura M, Kitawaki T, Hishizawa M, Kawaguchi-Sakita N, Fujii T, Taura D, Sone M, Inagaki N. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. PLoS One 2019;14:e0216954. [PMID: 31086392 DOI: 10.1371/journal.pone.0216954] [Cited by in Crossref: 67] [Cited by in F6Publishing: 71] [Article Influence: 16.8] [Reference Citation Analysis]
91 Koyama J, Horiike A, Yoshizawa T, Dotsu Y, Ariyasu R, Saiki M, Sonoda T, Uchibori K, Nishikawa S, Kitazono S, Yanagitani N, Ninomiya H, Ishikawa Y, Nishio M. Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer. J Thorac Dis 2019;11:1919-28. [PMID: 31285885 DOI: 10.21037/jtd.2019.04.102] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
92 Nuralieva NF, Troshina EA, Melnichenko GA. Lesions in endocrine glands as a complication of immunotherapy in the practice of oncologist. Clin Exp Thyroid 2019;14:174-182. [DOI: 10.14341/ket9875] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
93 Sanchez K, Page DB, Urba W. Immunotherapy Toxicities. Surg Oncol Clin N Am 2019;28:387-401. [PMID: 31079795 DOI: 10.1016/j.soc.2019.02.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
94 Peiró I, Palmero R, Iglesias P, Díez JJ, Simó-Servat A, Marín JA, Jiménez L, Domingo-Domenech E, Mancho-Fora N, Nadal E, Villabona C. Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes. Endocrine 2019;64:605-13. [PMID: 30805887 DOI: 10.1007/s12020-019-01871-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
95 Nivolumab. Reactions Weekly 2018;1730:228-228. [DOI: 10.1007/s40278-018-55128-6] [Reference Citation Analysis]
96 Kimbara S, Fujiwara Y, Iwama S, Ohashi K, Kuchiba A, Arima H, Yamazaki N, Kitano S, Yamamoto N, Ohe Y. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab. Cancer Sci 2018;109:3583-90. [PMID: 30230649 DOI: 10.1111/cas.13800] [Cited by in Crossref: 76] [Cited by in F6Publishing: 82] [Article Influence: 15.2] [Reference Citation Analysis]
97 Calabrese LH, Calabrese C, Cappelli LC. Rheumatic immune-related adverse events from cancer immunotherapy. Nat Rev Rheumatol 2018;14:569-79. [DOI: 10.1038/s41584-018-0074-9] [Cited by in Crossref: 107] [Cited by in F6Publishing: 115] [Article Influence: 21.4] [Reference Citation Analysis]